- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Metastases: Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer (clinicaltrials.gov) - Feb 11, 2020 P2, N=16, Terminated, PICNPs are a promising strategy for intraperitoneal treatment at the time of primary or interval debulking. N=77 --> 16 | Active, not recruiting --> Terminated; Inadequate toxicity
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Surgery, Metastases, Post-surgery: Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Feb 11, 2020 P2, N=19, Terminated, N=77 --> 16 | Active, not recruiting --> Terminated; Inadequate toxicity N=103 --> 19 | Recruiting --> Terminated; Toxicity and lack of efficacy
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab associated dermal filler reaction. (Pubmed Central) - Feb 8, 2020 He developed significant inflammation around the dermal filler sites after first cycle of cetuximab which improved with dissolution of the dermal fillers with hyaluronidase. This suggests that cetuximab can lead to inflammation around the dermal filler sites, which can be treated with dissolution of the filler.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab-Associated Pneumatosis Intestinalis. (Pubmed Central) - Feb 7, 2020 Altogether, our findings indicate that TGF-beta-activated CAFs play a role in limiting cetuximab efficacy in HNC. No abstract available
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, PD(L)-1 Biomarker, Surgery, Metastases: Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 5, 2020 P1/2, N=44, Active, not recruiting, Upon validation, our findings would provide novel insight for selecting treatment strategies. Trial primary completion date: Jan 2020 --> Apr 2020
- |||||||||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment closed, Metastases: ANCHOR-CRC: Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (clinicaltrials.gov) - Feb 5, 2020 P2, N=95, Active, not recruiting, Trial primary completion date: Jan 2020 --> Apr 2020 Recruiting --> Active, not recruiting
- |||||||||| cisplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: a retrospective study. (Pubmed Central) - Jan 31, 2020 Moreover, combining serial tumor biopsy, liquid biopsy, and radiologic imaging could help to define mechanisms of drug resistance and to guide selection of therapeutic strategies. Repeated HPP treatments with mitomycin C plus cisplatin, followed by cetuximab targeted-therapy, may represent a safe and efficacious palliative therapy in patients with unresectable recurrent rectal cancer, in progression following standard systemic chemo- and radio-therapy, and thus warrants confirmation in a larger phase III study.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 31, 2020 P1, N=28, Recruiting, Repeated HPP treatments with mitomycin C plus cisplatin, followed by cetuximab targeted-therapy, may represent a safe and efficacious palliative therapy in patients with unresectable recurrent rectal cancer, in progression following standard systemic chemo- and radio-therapy, and thus warrants confirmation in a larger phase III study. Trial completion date: Apr 2020 --> Apr 2021 | Trial primary completion date: Apr 2020 --> Apr 2021
- |||||||||| Trial primary completion date, Combination therapy: Bevacizumab in Multiple Phase I Combinations (clinicaltrials.gov) - Jan 30, 2020
P1, N=354, Active, not recruiting, Trial completion date: Apr 2020 --> Apr 2021 | Trial primary completion date: Apr 2020 --> Apr 2021 Trial primary completion date: Oct 2019 --> Oct 2020
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Ratiometric bioluminescent sensor proteins based on intramolecular split luciferase complementation. (Pubmed Central) - Jan 29, 2020 The new sensor design also improved the dynamic response of a sensor for the therapeutic antibody cetuximab 4-fold, allowing the direct quantification of this anti-EGFR antibody in undiluted blood plasma. The modular sensor architecture allows easy and systematic tuning of a sensor's dynamic range and should be generally applicable to allow rational engineering of bioluminescent sensor proteins.
- |||||||||| Enrollment open, Trial completion date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: SU2C ACT3: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (clinicaltrials.gov) - Jan 27, 2020
P3, N=400, Recruiting, The therapeutic sequence of regorafenib followed by cetuximab suggests a longer OS than the current standard sequence. Not yet recruiting --> Recruiting | Trial completion date: Feb 2022 --> Feb 2023 | Trial primary completion date: Feb 2021 --> Feb 2022
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Drivers of Secondary Resistance to Anti-Egfr Therapy in Metastatic Colorectal Cancer (atrium) - Jan 25, 2020 - Abstract #DKK2020DKK_2417; Taken together, these results support a role of IGF2 and FGFs as candidate proteins conferring SR in an autocrine fashion in the setting of KRAS wild-type mCRC under chronic anti-EGFR treatment. Importantly, these results also suggest that potential combination therapies of Cmab and an IGF2 or FGF inhibitor could prevent establishment of SR and offer new treatment opportunities for patients with SR mCRC.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Case of Two Patients with MSI-High Metastatic Colorectal Cancer Treated with Pembrolizumab (Room A2) - Jan 25, 2020 - Abstract #DKK2020DKK_2050; Therefore, we emphasize the importance of testing for MSI. Further clinical studies are needed in order to verify efficacy and safety of ICI in mCRC patients and to identify those patients with MSI-high mCRC that do not benefit from ICI therapy.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab and Radiation Therapy in Head and Neck Cancer. (Pubmed Central) - Jan 24, 2020 Despite lack of significant OS increase, taxane based TPEx regimen appears to be a new option in 1st line R/M HNSSCC, with a shorter time on CT and significantly lower toxicity than the EXTREME regimen. No abstract available
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Enrollment change, Trial withdrawal, Metastases: AlloStim (clinicaltrials.gov) - Jan 22, 2020 P2/3, N=0, Withdrawn, Not yet recruiting --> Recruiting N=450 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Review, Journal: Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. (Pubmed Central) - Jan 21, 2020 Intriguingly, these subclonal events largely seem to converge on RAS/RAF/MAPK pathway in patients treated with EGFR-targeted monoclonal antibodies. This review describes the clinical and biological evolution and development of EGFR targeted therapies in mCRC, the challenges in the presence of molecular complexities, the role of cell free (cf)-DNA and future strategies that could lead to further optimal discovery of clinically meaningful biomarkers and application of precision medicine.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Clinical, Review, Journal: MicroRNAs in cancer drug resistance: Basic evidence and clinical applications. (Pubmed Central) - Jan 19, 2020 In this study, we review the mechanisms of tumor cell resistance to mAb therapies and the role of miRNAs therein. Emerging treatment strategies combine therapies using innovative miRNA mimics or antagonizers with conventional approaches to maximize outcomes of patients with cancer.
|